Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02732587 · ClinicalTrials.gov registry record · Phase 1
Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02732587 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 5 participants.
The verdict
NCT02732587, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this alcohol-interaction pilot study is to provide information on the effect of AZD0530 (Saracatinib) on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test the effects of a single dose of AZD0530 (125 mg) on alcohol related responses. This is a within subjects open label study in which the investigators plan to run 8 subjects to obtain 5 completers.
Interventions
- DRUG Saracatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-11 |
| Est. Completion | 2016-03-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02732587
The ClinicalTrials.gov registry entry for NCT02732587 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Saracatinib is the first listed.
NCT02732587 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02732587 about?
NCT02732587 is a clinical study titled "Investigating the Interactions of AZD0530 With Alcohol in Social Drinkers". The purpose of this alcohol-interaction pilot study is to provide information on the effect of AZD0530 (Saracatinib) on the pharmacokinetics of alcohol and on alcohol responses, including stimulation, sedation, intoxication, body sway and physiological responses. The investigators propose to test th...
What is the current status of trial NCT02732587?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-11. Estimated completion is 2016-03-23.
What interventions are being tested in trial NCT02732587?
The interventions under investigation include: Saracatinib (DRUG).
Who is sponsoring clinical trial NCT02732587?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.